

Committee minutes

Termination of Pregnancy Committee meeting 3

Date: 27/02/2018

Location: RCOG, London

Minutes: Confirmed



Committee members present:	
Iain Cameron (Chair)	(Present for notes 1-17)
Sharon Cameron (Topic adviser)	(Present for notes 1-17)
Joanne Fletcher	(Present for notes 1-17)
Kati Gray	(Present for notes 3-17)
Patricia Lohr	(Present for notes 1-17)
Jonathan Lord	(Present for notes 1-17)
Sarah Makstutis	(Present for notes 1-17)
Michael Nevill	(Present for notes 1-17)
Kate Randall	(Present for notes 7-17)
Clare Searle	(Present for notes 1-14)
Peter Taylor	(Present for notes 2-17)

In attendance:		
Gareth Haman	NICE Senior Medical Editor	(Present for notes 10 – 15)
Nick Staples	NICE Guideline Commissioning Manager	(Present for notes 1-17)
Angela Bennett	NGA Guideline Lead	(Present for notes 1-17)
Melanie Davies	NGA Clinical Advisor	(Present for notes 1-3, 6-17)
Elise Hasler	NGA Information Scientist	(Present for notes 1-14)
Eleanor Howat	NGA Project Manager	(Present for notes 1-17)
Laura O'Shea	NGA Systematic Reviewer	(Present for notes 1-17)
Mia Schmidt-Hansen	NGA Senior Systematic Reviewer	(Present for notes 4-6, 10-17)
Kelly Williams	NGA Systematic Reviewer	(Present for notes 1-17)

Committee minutes

Observers	
Gareth Murphy (NICE Business Analyst)	(Present for notes 1-17)

Apologies:	
Alex Bates	NGA Health Economist

1a. Welcome and objectives for the meeting				
<p>The Chair welcomed the Committee members and attendees to the third meeting on Termination of Pregnancy.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included: preparing review protocols and PICOs, reviewing evidence and making recommendations.</p>				
1b. Confirmation of matter under discussion, declarations of interest, and signing off the minutes of GC1				
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was termination of pregnancy.</p> <p>The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. The following interests were declared:</p>				
Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Iain Cameron	Dean of the Faculty of Medicine, University of Southampton	I am a non-executive director of the Medical and Dental Defence Union of Scotland, co-opted to the Board in April 2017 and formally appointed in September 2017. This is a paid role. [declared 22.01.2018]	Personal, financial, non-specific	Declare and participate
Sharon Cameron	Clinical Lead for Sexual and Reproductive Health services, NHS Lothian	Member of BSACP British society of abortion care providers since 2015 [declared 18/02/2018]	Personal, non-financial, specific	Declare and continue

Committee minutes

<p>Sharon Cameron</p>	<p>Clinical Lead for Sexual and Reproductive Health services, NHS Lothian</p>	<p>President of FIAPAC (International Federation of Abortion & Contraception Professionals). As President I am the chair of the scientific organising committee for the international congress. I give the welcome and closing words at the congress. I chair board meetings. I write the forward for the FIAPAC newsletter. [declared 18/02/2018]</p>	<p>Personal, non-financial, specific</p>	<p>Declare and continue</p>
<p>Jonathan Lord</p>	<p>Consultant in Obstetrics & Gynaecology, Royal Cornwall Hospital</p>	<p>Whilst I have previously had private practice privileges granted in a local hospital, I have never taken these up and they would no longer be valid. I do treat IVF patients for whom NHS funding is denied and who therefore have to self-fund. I don't view this as different to my NHS work (in that the cost of treatment is merely directed to the patient rather than to their CCG who should be paying), but owing to the complexity of the invoicing system we have to administer this through a limited company of which I am a director. Through our company we organise the split of funds to the various parties (IVF lab, our own hospital Trust and our own payments). Rather than take a salary or get paid via the Trust for our time, we simply have twice yearly payments via dividends. This is only applicable to my fertility (assisted conception) work and there is no cross over to TOP. I have never received income from a patient to provide TOP services, and have never</p>	<p>Personal, financial, non-specific</p>	<p>Declare and participate</p>

Committee minutes

		taken out indemnity insurance for any private work. [declared 27.11.2017; form submitted 24.1.2018]		
<p>The Chair and a senior member of the Developer's team noted that Joanne Fletcher has a conflict of interest with question 2.8 and cannot participate in discussion during agenda item 3.</p> <p>The Chair and a senior member of the Developer's team noted that the other interests declared did not prevent the attendees from fully participating in the meeting.</p> <p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>				
2. Presentation on Expenses				
<p>The Chair introduced Eleanor Howat, NGA Project Manager, who gave a presentation on end of financial year expense claims.</p>				
3 – 5. Signing off of review protocols				
<p>The Chair introduced Kelly Williams, NGA Systematic Reviewer, Laura O'Shea, NGA Systematic Reviewer and Mia Schmidt-Hansen, NGA Senior Systematic Reviewer, who led a discussion with the committee to sign off the protocols for the following review questions:</p> <ul style="list-style-type: none">• 2.8 What is the effectiveness, safety and acceptability of surgical compared to medical termination in the second trimester?• 2.9 For women who are having an early (up to 10 weeks) medical termination of pregnancy, what is the effectiveness, safety and acceptability of mifepristone and misoprostol given simultaneously compared with other time intervals?• 2.11 What is the optimal dose and route of administration of misoprostol after mifepristone, for inducing medical termination in the second trimester?				
6 – 8. Presentation and discussion of review protocols				
<p>The Chair introduced Kelly Williams, NGA Systematic Reviewer, Laura O'Shea, NGA Systematic Reviewer and Mia Schmidt-Hansen, NGA Senior Systematic Reviewer who led a discussion with the committee to finalise and sign off the protocols for the</p>				

Committee minutes

following review questions:

- 2.1 Is it safe and effective to start termination before there is ultrasound evidence of an intrauterine pregnancy?
- 2.10 For women who are having medical termination of pregnancy, what gestational limit for expulsion at home offers the best balance of benefits and harms?
- 3.1 What is the best method of excluding an ongoing pregnancy after early (up to 10 weeks) medical termination of pregnancy, when the expulsion has not been witnessed by healthcare professionals (for example, expulsion at home)?

10 - 11. Signing off of review protocols

The Chair introduced Kelly Williams, NGA Systematic Reviewer, Laura O'Shea, NGA Systematic Reviewer and Mia Schmidt-Hansen, NGA Senior Systematic Reviewer, who led a discussion with the committee to sign off the protocols for the following review questions:

- 1.1 What information should women who have requested a termination of pregnancy be given before they have the procedure?
- 3.3 What support should women be offered after a termination of pregnancy?

12 – 14. Presentation of PICOs

The Chair introduced Kelly Williams, NGA Systematic Reviewer, Laura O'Shea, NGA Systematic Reviewer and Mia Schmidt-Hansen, NGA Senior Systematic Reviewer, who led a discussion with the committee about the PICOs for the following review questions:

- 4.1 What strategies ensure the sustainability of a safe and accessible termination of pregnancy service?
- 4.2 What strategies prevent delayed presentation to termination of pregnancy services?
- 4.3 What strategies are effective at facilitating uptake of effective contraception after termination of pregnancy?

15. Presentation of evidence review 3.2

The Chair introduced Mia Schmidt-Hansen, NGA Senior Systematic Reviewer, who gave a presentation on EVIDENCE REVIEW: 3.2 For women who have had medical

Committee minutes

termination of pregnancy, how soon afterwards is it safe to insert an intrauterine contraceptive device?

The committee reviewed the clinical evidence, discussed and drafted recommendations, and agreed the content of the rationale and impact sections of the evidence report. The committee also discussed equalities issues for the question and agreed that the draft recommendation addressed these.

16. Any other business

The NGA systematic reviewers raised the issue of large study results for review questions 2.6. The committee agreed a set of restrictions to be placed on the results to reduce the amount of evidence for the review. These were captured in the actions and decisions log for the meeting.

Date of next meeting: 10/04/2018

Location of next meeting: RCOG, London